Erasca Receives FDA Fast Track Status for Pancreatic Cancer Drug Candidate

Erasca, Inc. announced that the FDA has granted Fast Track Designation to ERAS-0015 for treating metastatic pancreatic adenocarcinoma. This designation aims to accelerate the development and review process for therapies addressing serious conditions with unmet medical needs. The move could potentially expedite the availability of a new treatment option for this severe cancer.